Profile data is unavailable for this security.
About the company
Glenmark Pharmaceuticals Limited is an India-based research-led, global pharmaceutical company. The Company hosts a diverse portfolio spanning branded, generics, and over the counter (OTC) segments. The Company is focused on the therapy areas of Respiratory, Dermatology and Oncology. The Company also has a regional/country-specific presence in other therapeutic areas like diabetes, cardiovascular and oral contraceptives. The Company’s offerings include complex injectables and biologics, oral solids, liquids, topical products, respiratory mdi1/dpi2/nasal sprays. The Company is focused on developing products for markets such as India, Russia & CIS, Brazil, Asia and Africa. Its brands include RYALTRIS and SALMEX / ASTHMEX. RYALTRIS, the Company's first global branded specialty drug for treating symptoms of seasonal allergic rhinitis. The Company's subsidiaries include Glenmark Pharmaceuticals Inc., Ichnos Sciences Inc., and Glenmark Holding SA.
- Revenue in INR (TTM)120.21bn
- Net income in INR-15.73bn
- Incorporated1977
- Employees14.99k
- LocationGlenmark Pharmaceuticals LtdB D S MargChakala, Off Western Express HighwayAndheri (E),MUMBAI 400099IndiaIND
- Phone+91 2 240189999
- Fax+91 2 240189986
- Websitehttps://glenmarkpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Laurus Labs Ltd | 50.54bn | 1.48bn | 270.31bn | 6.01k | 182.78 | -- | 48.91 | 5.35 | 2.74 | 2.74 | 93.40 | -- | -- | -- | -- | 8,413,434.00 | -- | 10.13 | -- | 16.47 | 52.80 | 47.63 | 3.01 | 12.83 | -- | 2.04 | -- | 13.00 | -16.55 | 17.07 | -79.68 | 11.36 | 21.68 | 21.67 |
| Pfizer Ltd | 22.25bn | 6.09bn | 270.95bn | 1.72k | 44.53 | -- | 40.45 | 12.18 | 133.01 | 133.01 | 486.27 | -- | -- | -- | -- | 12,926,610.00 | -- | 14.22 | -- | 17.71 | 65.06 | 61.37 | 27.35 | 24.05 | -- | 43.74 | -- | 82.67 | -9.55 | 1.05 | -11.64 | 5.14 | 33.35 | 9.24 |
| Natco Pharma Ltd. | 42.21bn | 16.37bn | 279.72bn | 4.02k | 17.09 | -- | 15.34 | 6.63 | 91.37 | 91.37 | 235.68 | -- | -- | -- | -- | 10,510,210.00 | -- | 12.33 | -- | 14.25 | 83.40 | 73.05 | 38.77 | 25.16 | -- | 91.13 | -- | 18.96 | 47.72 | 13.81 | 94.09 | 16.59 | -5.76 | 14.87 |
| Emcure Pharmaceuticals Ltd | -100.00bn | -100.00bn | 282.44bn | 11.15k | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 7.14 | -- | 13.93 | -- | 59.29 | -- | 7.81 | -- | -- | -- | 0.00 | 11.23 | 7.14 | -6.36 | 21.35 | -5.93 | -- |
| J B Chemicals and Pharmaceuticals Ltd | 35.92bn | 5.87bn | 291.31bn | 5.31k | 50.71 | -- | 39.64 | 8.11 | 36.99 | 36.99 | 226.16 | -- | -- | -- | -- | 6,764,044.00 | -- | 15.77 | -- | 18.89 | 66.27 | 61.18 | 16.34 | 16.06 | -- | 21.04 | -- | 33.08 | 10.63 | 16.22 | 34.84 | 23.36 | 40.15 | 37.42 |
| Suven Pharmaceuticals Ltd | 9.34bn | 2.40bn | 294.72bn | 1.05k | 122.43 | -- | 99.60 | 31.54 | 9.46 | 9.46 | 36.75 | -- | -- | -- | -- | 8,883,019.00 | -- | 23.17 | -- | 26.20 | 56.59 | 58.85 | 25.73 | 33.21 | -- | 33.74 | -- | 18.63 | -21.56 | 22.71 | -26.99 | 22.41 | -1.83 | -- |
| Gland Pharma Ltd | 58.58bn | 7.22bn | 304.07bn | 4.22k | 42.11 | -- | 27.81 | 5.19 | 43.83 | 43.83 | 355.57 | -- | -- | -- | -- | 13,890,770.00 | -- | 13.23 | -- | 14.56 | 61.00 | 55.58 | 12.33 | 22.92 | -- | 34.66 | -- | 7.26 | 56.29 | 22.61 | -1.10 | 11.32 | 24.02 | -- |
| Piramal Pharma Ltd | 83.73bn | 277.60m | 306.78bn | 6.72k | 1,103.36 | -- | 39.37 | 3.66 | 0.2107 | 0.2107 | 64.75 | -- | -- | -- | -- | 12,462,350.00 | -- | -- | -- | -- | 64.15 | -- | 0.3315 | -- | -- | 7.12 | -- | -- | 15.39 | -- | 109.56 | -- | -- | -- |
| IPCA Laboratories Ltd | 82.12bn | 5.77bn | 369.62bn | 17.34k | 64.08 | -- | 38.96 | 4.50 | 22.74 | 22.74 | 323.71 | -- | -- | -- | -- | 4,737,502.00 | -- | 10.33 | -- | 13.52 | 67.08 | 59.16 | 6.84 | 12.25 | -- | 15.41 | -- | 12.86 | 23.39 | 15.35 | 16.13 | 4.24 | 17.90 | 21.67 |
| Ajanta Pharma Ltd | 43.33bn | 8.54bn | 393.35bn | 7.84k | 46.45 | -- | 39.73 | 9.08 | 67.79 | 67.79 | 343.97 | -- | -- | -- | -- | 5,523,445.00 | -- | 16.61 | -- | 20.47 | 75.01 | 73.22 | 19.71 | 19.31 | -- | -- | -- | 31.20 | 12.45 | 15.41 | 38.81 | 16.10 | -14.97 | 10.76 |
| GlaxoSmithKline Pharmaceuticals Limited | 35.07bn | 6.40bn | 474.15bn | 3.21k | 74.10 | -- | 66.80 | 13.52 | 37.77 | 37.77 | 206.98 | -- | -- | -- | -- | 10,920,890.00 | -- | 11.01 | -- | 17.88 | 61.97 | 55.77 | 18.25 | 12.25 | -- | 490.08 | -- | 192.07 | 6.21 | 2.00 | -2.91 | 5.78 | -36.02 | 9.86 |
| Glenmark Pharmaceuticals Ltd | 120.21bn | -15.73bn | 483.39bn | 14.99k | -- | -- | -- | 4.02 | -55.78 | -46.50 | 425.96 | -- | -- | -- | -- | 8,020,026.00 | -- | 1.02 | -- | 1.43 | 63.93 | 59.47 | -12.71 | 1.43 | -- | 1.78 | -- | 56.98 | 1.98 | 3.67 | -1,018.93 | -- | -5.89 | 4.56 |
| Abbott India Ltd | 59.28bn | 12.39bn | 613.27bn | 3.81k | 49.50 | -- | 46.77 | 10.35 | 583.08 | 583.08 | 2,789.54 | -- | -- | -- | -- | 15,541,480.00 | -- | 20.92 | -- | 28.59 | 45.28 | 44.20 | 20.90 | 17.26 | -- | 119.46 | -- | 77.06 | 9.35 | 9.72 | 26.52 | 21.68 | 31.08 | 52.32 |
Data as of Sep 18 2024. Currency figures normalised to Glenmark Pharmaceuticals Ltd's reporting currency: Indian Rupee INR
22.53%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| HSBC Global Asset Management (Hong Kong) Ltd.as of 31 Dec 2023 | 9.95m | 3.53% |
| HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 31 Aug 2024 | 8.87m | 3.14% |
| Capital Research & Management Co. (World Investors)as of 30 Jun 2024 | 8.82m | 3.13% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 6.36m | 2.26% |
| Life Insurance Corporation of India (Investment Portfolio)as of 30 Jun 2023 | 6.27m | 2.22% |
| Mirae Asset Investment Managers (India) Pvt Ltd.as of 31 Aug 2024 | 6.21m | 2.20% |
| The Vanguard Group, Inc.as of 04 Sep 2024 | 5.64m | 2.00% |
| NTAsset (Thailand) Co., Ltd.as of 30 Jun 2023 | 4.13m | 1.46% |
| Dimensional Fund Advisors LPas of 05 Sep 2024 | 3.77m | 1.34% |
| Aditya Birla Sun Life Amc Ltd. (Investment Management)as of 31 Aug 2024 | 3.56m | 1.26% |
More ▼
Data from 01 Jan 1960 - 12 Sep 2024Source: FactSet Research Systems Inc.
